Author name: Leonardo Arias

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The company also posted weaker third-quarter results, but CEO David Fischel said orders for the new GenesisX system, when fully launched, would outpace the rate for an older model.

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.

C-suite executives surveyed said they think new technology leadership roles will become more important in the next three years, according to a report from the Healthcare Financial Management Association.

The lowest level of quarterly VC funding since 2023 has tempered expectations that the sector will achieve its best year since 2021.

The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company expects to generate initial Phase I data for its lead asset MGX-001 in hemophilia A.

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright.

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.

El conjunto de satélites Sentinel-1, que proporciona visión por radar al programa de observación de la Tierra Copernicus, cuenta con una nueva incorporación a su familia gracias a la puesta en órbita del Sentinel-1D, el último de la innovadora primera genera …